



# **Recruiting & Retaining More Patients Per Site**

*A Global ALS Case Study*

## Case Study Outcome

### Indication: ALS

*HTS enhances recruitment and retention rates in ALS trials by enabling in-home visits, reducing the burden of travel, and ensuring continuous data collection even as patients' mobility declines.*

*Here's what our team was able to do...*

<b>12</b>	Countries across Europe, North America and Oceania
<b>814</b>	Patients referred to Home Trial Support
<b>4,877</b>	Home Trial Support visits conducted during the study
<b>90%</b>	Patient retention rate to Home Trial Support
<b>33%</b>	Faster recruitment than planned

## Breaking Down Participation Barriers *delivering wherever patients live*

For patients with ALS, participating in clinical trials can be daunting due to the unique and multifaceted burdens they face. The progressive nature of ALS often limits mobility, making regular travel to clinical sites physically exhausting or outright impossible. Many patients require assistance with daily activities and may depend on caregivers, further complicating their ability to attend site-based visits.

The emotional toll of living with ALS, coupled with the logistical challenges of arranging transportation, time off work, or childcare, often deters potential participants.

**Home Trial Support (HTS) services can play a pivotal role in addressing these barriers, enhancing accessibility and participation in ALS trials.**

By bringing trial visits directly to patients' homes, HTS services eliminate the need for travel and provides care in a familiar and comfortable environment. This approach accommodates patients' physical limitations, reduces caregiver burden, and fosters higher retention and compliance rates. HTS services ensure that even patients with advanced disease stages, who might otherwise be excluded due to their inability to visit a site, can contribute to vital research.




## Key Outcomes & Impact of HTS

- 85% of patients enrolled in the study utilized Home Trial Support
- Patient retention to Home Trial Support was maintained at over 90%
- On average, 128 patients per month were referred to Home Trial Support during the recruitment period
- In total, 82% of patients were referred to MRN from 94% of sites that utilized the service
- Sites in North America referred, on average, 9.5 patients to Home Trial Support; sites in Europe referred an average of 12.9 patients
- High volume of visits; over 300 visits completed per month for 11 consecutive months during ongoing treatment
- Due to the rapid deterioration of patients, our project management team efficiently adapted to deliver unscheduled visits and scale visit volume to meet patient needs.

**Recruitment completed in 6 months; 33% faster than planned.**

**Patient recruitment at sites utilizing Home Trial Support was 16% better than sites that did not.**



## MRN's Experience In Central Nervous System Clinical Trials

Our team has supported **Central Nervous System** studies in **22 countries** for **14+ years**, providing services such as Blood Draws and IMP Admin via IV Infusion and Subcutaneous Injection.

**22 countries**

supported with HTS services

**38 trials**

supported with HTS services

**681 sites**

trained for Home Trial Support

**2,679 patients**

referred to Home Trial Support

**32,492 HTS**

visits performed

## Delivering Quality And Maintaining Patient Safety

MRN is a global leader in Home Trial Support (HTS) services, bringing clinical trials to patients' homes to remove participation barriers and enhance trial efficiency. By expanding the geographical reach of clinical trials, HTS improves accessibility and inclusivity while ensuring trial visits fit patients' schedules.

For patients, HTS eliminates challenges like mobility limitations, travel distance, and scheduling conflicts. For sponsors and sites, it accelerates recruitment, improves retention, and enhances compliance, leading to better data and faster trial completion. **With 112,500+ home trial visits across 99+ countries and experience in 100+ indications**, MRN delivers trials across all phases and therapeutic areas.

Our healthcare professionals conduct in-home procedures, from patient training and assessments to complex drug administration and direct data capture. While visits happen at home, the Principal Investigator (PI) retains full oversight, ensuring trial integrity and patient safety.

MRN upholds the highest standards in patient and data safety. Our healthcare professionals complete rigorous, protocol-specific training with 100% accuracy, and we maintain **ISO27001 and ISO 9001:2015 accreditation** for strict regulatory compliance. With a proven track record in safe, efficient, and patient-focused HTS, MRN is making clinical trials more accessible and inclusive worldwide.

# Delivering Community-Based Trials

*focused on patients, focused on results*

With our Home Trial Support services, we remove participation barriers by bringing trials to patients where they live, creating convenience and comfort that results in **increased recruitment and retention**.



Our project management and visit delivery team have a strong understanding of **global regulations for in-home care** and are able to collaborate directly with the Sponsor and country managers to expand services, ensuring patients receive necessary home visits as their needs grow.

*“We act as a single provider with global delivery. This means we can scale quickly and efficiently to deliver where patients live.”*

**Stuart Redding, CEO, MRN**



# Our offices



## UK

Medical Research Network Ltd  
Milton Keynes



## USA

Medical Research Network Inc.  
Deerfield IL



## Spain

Medical Research Network  
Madrid



## Germany

Medical Research Network Germany GmbH  
Stuttgart-Vaihingen



## Japan

Medical Research Network Japan KK  
Tokyo



## France

Medical Research Network,  
Lyon



[enquiries@themrn.co.uk](mailto:enquiries@themrn.co.uk)



[www.themrn.io](http://www.themrn.io)

